These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19619717)

  • 1. Ranibizumab for uveitic macular edema: why?
    Gaudio PA
    Am J Ophthalmol; 2009 Aug; 148(2):179-80. PubMed ID: 19619717
    [No Abstract]   [Full Text] [Related]  

  • 2. Ranibizumab for refractory uveitis-related macular edema.
    Acharya NR; Hong KC; Lee SM
    Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab vs. triamcinolone.
    Soheilian M; Rabbanikhah Z; Ramezani A; Kiavash V; Yaseri M; Peyman GA
    Ophthalmology; 2010 Apr; 117(4):855-855.e2. PubMed ID: 20346835
    [No Abstract]   [Full Text] [Related]  

  • 4. Local therapeutic options for uveitic cystoid macular edema.
    Slean GR; Khurana RN
    Int Ophthalmol Clin; 2015; 55(3):39-61. PubMed ID: 26035761
    [No Abstract]   [Full Text] [Related]  

  • 5. Vascular endothelial growth factor inhibition in uveitis: a systematic review.
    Gulati N; Forooghian F; Lieberman R; Jabs DA
    Br J Ophthalmol; 2011 Feb; 95(2):162-5. PubMed ID: 20494915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin).
    Ziemssen F; Deuter CM; Stuebiger N; Zierhut M
    Graefes Arch Clin Exp Ophthalmol; 2007 Jun; 245(6):917-8. PubMed ID: 17219112
    [No Abstract]   [Full Text] [Related]  

  • 7. [Angiogenesis inhibitors for vision loss. Ranibizumab for macular degeneration].
    Mohr-Andrä M; Mohr K
    Pharm Unserer Zeit; 2007; 36(6):437-40. PubMed ID: 17957687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab for retinal neovascularization.
    Jorge R; Oliveira RS; Messias A; Almeida FP; Strambe ML; Costa RA; Scott IU
    Ophthalmology; 2011 May; 118(5):1004-1004.e1. PubMed ID: 21539985
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravitreal Antiangiogenic Therapy of Uveitic Macular Edema: A Review.
    Kozak I; Shoughy SS; Stone DU
    J Ocul Pharmacol Ther; 2017 May; 33(4):235-239. PubMed ID: 28165851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical review: Update on treatment of inflammatory macular edema.
    Ossewaarde-van Norel A; Rothova A
    Ocul Immunol Inflamm; 2011 Feb; 19(1):75-83. PubMed ID: 21034302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
    Hohman TC
    Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for age-related macular degeneration.
    Patel S
    Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring ocular drug therapy by analysis of aqueous samples.
    Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
    Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of uveitic macular edema with acetazolamide.
    Zierhut M; Thiel HJ; Schlote T
    Doc Ophthalmol; 1999; 97(3-4):409-13. PubMed ID: 10896357
    [No Abstract]   [Full Text] [Related]  

  • 19. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies.
    Wong TY
    Am J Ophthalmol; 2009 Sep; 148(3):327-9. PubMed ID: 19703607
    [No Abstract]   [Full Text] [Related]  

  • 20. Uveitis treatment trials--a cross-study perspective.
    Cunningham ET; Goldstein DA; Zierhut M
    Ocul Immunol Inflamm; 2012 Apr; 20(2):63-7. PubMed ID: 22360435
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.